SCHEMBL483939

SCHEMBL483939

COC(COC(=O)Nc1ccc(N2CCOCC2)c(F)c1)OC

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LDHA P00338 2/20 0.56
LDHB P07195 2/20 0.56
HTT P42858 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 4/20 0.53
KMT2A Q03164 1/20 0.52
MAPT P10636 2/20 0.50
MTOR P42345 2/20 0.49
DGAT1 O75907 1/20 0.47
LMNA P02545 1/20 0.47
KDM4E B2RXH2 1/20 0.47
F10 P00742 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406029 0.85 HTT (0.58) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL5216754 0.85 HTT (0.63) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL16204421 0.84 HTT (0.60) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL30771563 0.80 NPC1 (0.61) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL2152084 0.80 NPC1 (0.61) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL484019 0.78 GAA (0.48) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL20922083 0.78 HTT (0.66) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL15440610 0.77 HTT (0.52) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL21479386 0.77 KDM4E (0.75) LDHALDHBHTTL3MBTL1NPC1
SCHEMBL6988691 0.76 HTT (0.67) LDHALDHBHTTL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD LDHA 287/4885LDHB 689/4885HTT 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.